Posts Tagged CRO

CDMOs Buttressed by Resilient Emerging Biopharma Sector

by

Publicly traded emerging biopharmaceutical companies increased their research and development (R&D) expenditure in the second quarter of 2017, reaching almost $3.9 billion, 45% greater than the spending level seen in the second quarter of 2015 (see Figure 1, below). Although the total R&D expenditure of emerging biopharma companies (around $15 billion annually) is a fraction […]

Learn more

AMRI Sold to PE Firms

by

Albany Molecular Research Inc. (AMRI) is being taken private in a deal that values the company at $922 million. The buyers, private equity firms The Carlyle Group and GTCR, are newcomers to the contract development and manufacturing organization (CDMO) space, although Carlyle also owns clinical contract research organization (CRO) PPD Inc. The investors are paying […]

Learn more

CMOs and CROs Have Different Trajectories

by

CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate. A growing number of observers, including the Wall Street analysts that follow the publicly-traded contract research organizations (CROs) and contract manufacturing organizations (CMOs), have made statements recently suggesting that the CMO industry is following the […]

Learn more

2016 Results Summary: A Rising Tide Lifts All Contract Service Boats

by

The Contract Development and Manufacturing Organization (CDMO) sector enjoyed a strong 2016, with all components reporting robust, albeit uneven, growth. Early-stage companies posted especially impressive results, bolstered by generous external funding, and the API sector continued its recent recovery, especially in the small molecule space (see Figure 1, below). The impressive top line results do, […]

Learn more

Time to Hit the Road!

by

The pharma trade show season is officially in full swing! Whether your organization is a CRO, CMO, CDMO or any other service provider to the pharma/biotech/device and diagnostics industry, chances are you’ve either recently attended, or will be attending, an industry event over the next few months. If this is the case, make sure you’re […]

Learn more

The Tide Stays High

by

Robust venture capital investment gives CDMOs and CROs a positive outlook for 2017. A year ago, the outlook for contract services was a little uncertain. Equity markets’ appetite for public offerings from emerging bio/pharmaceutical companies had significantly diminished: valuations of emerging bio/pharma companies, as measured by the NASDAQ Biotechnology Index (NBI), had declined by 15% […]

Learn more

Slower Bio/Pharma Investment Could Hurt CDMOs in 2017

by

Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) may not be feeling it yet, but the downturn in external financing for early stage bio/pharma companies is real. The impact on CDMOs and CROs will be delayed, but there is no doubt that service providers will be feeling it in coming months. Two […]

Learn more

Territory Watch:
Look Beyond the Usual to Capture New Business

by

The majority of bio/pharma funding events in the U.S. during 2014 and 2015 occurred outside the high-profile hubs of the San Francisco Bay Area and Boston. However, contract research organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) looking to capture new business will find substantial opportunities in geographically concentrated areas far beyond those more […]

Learn more

European Clinical Pipeline Activity

by

Until the recent downturn in external financing for early stage biopharma companies, the past couple of years had witnessed something of a renaissance in biopharma funding, led as usual, by the United States. The positive mood had spread beyond the US, and this was reflected in a significant increase in pipeline activity emanating from companies […]

Learn more

It’s Getting Harder for Bio/Pharma to Raise Money

by

Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) may not be feeling it yet, but the downturn in external financing for early stage bio/pharma companies is real. Two recent articles in the financial press underscore what has been happening. Bloomberg chronicled the challenges early stage public companies are facing as they go out for […]

Learn more